<PAPER><mode2 name='PMC3457029' hasDoc='yes' version='597'></mode2><article xmlns:mml='http://www.w3.org/1998/Math/MathML' xmlns:xlink='http://www.w3.org/1999/xlink' article-type='research-article'><front><journal-meta><journal-id journal-id-type='nlm-ta'>Dement Geriatr Cogn Dis Extra</journal-id><journal-id journal-id-type='iso-abbrev'>Dement Geriatr Cogn Dis Extra</journal-id><journal-id journal-id-type='publisher-id'>DEE</journal-id><journal-title-group><journal-title>Dementia and Geriatric Cognitive Disorders EXTRA</journal-title></journal-title-group><issn pub-type='ppub'>1664-5464</issn><issn pub-type='epub'>1664-5464</issn><publisher><publisher-name>S. Karger AG</publisher-name><publisher-loc>Allschwilerstrasse 10, P.O. Box · Postfach · Case postale, CH–4009, Basel, Switzerland · Schweiz · Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.ch</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type='pmcid'>3457029</article-id><article-id pub-id-type='doi'>10.1159/000341780</article-id><article-id pub-id-type='publisher-id'>dee-0002-0353</article-id><article-categories><subj-group subj-group-type='heading'><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title><s sid='1'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>Serum Granulocyte Colony-Stimulating Factor and Alzheimer's Disease</s></article-title></title-group><contrib-group><contrib contrib-type='author'><name><surname>Barber</surname><given-names>Robert C.</given-names></name><xref rid='aff1' ref-type='aff'><sup>a</sup></xref><xref rid='aff2' ref-type='aff'><sup>b</sup></xref><xref rid='cor1' ref-type='corresp'>*</xref></contrib><contrib contrib-type='author'><name><surname>Edwards</surname><given-names>Melissa I.</given-names></name><xref rid='aff5' ref-type='aff'><sup>e</sup></xref></contrib><contrib contrib-type='author'><name><surname>Xiao</surname><given-names>Guanghua</given-names></name><xref rid='aff6' ref-type='aff'><sup>f</sup></xref></contrib><contrib contrib-type='author'><name><surname>Huebinger</surname><given-names>Ryan M.</given-names></name><xref rid='aff7' ref-type='aff'><sup>g</sup></xref></contrib><contrib contrib-type='author'><name><surname>Diaz-Arrastia</surname><given-names>Ramon</given-names></name><xref rid='aff8' ref-type='aff'><sup>h</sup></xref></contrib><contrib contrib-type='author'><name><surname>Wilhelmsen</surname><given-names>Kirk C.</given-names></name><xref rid='aff9' ref-type='aff'><sup>i</sup></xref></contrib><contrib contrib-type='author'><name><surname>Hall</surname><given-names>James R.</given-names></name><xref rid='aff1' ref-type='aff'><sup>a</sup></xref><xref rid='aff3' ref-type='aff'><sup>c</sup></xref></contrib><contrib contrib-type='author'><name><surname>O'Bryant</surname><given-names>Sid E.</given-names></name><xref rid='aff1' ref-type='aff'><sup>a</sup></xref><xref rid='aff4' ref-type='aff'><sup>d</sup></xref><on-behalf-of>for the Texas Alzheimer's Research and Care Consortium</on-behalf-of><xref rid='other1' ref-type='other'><sup>1</sup></xref></contrib></contrib-group><aff id='aff1'><sup>a</sup>Institute of Aging and Alzheimer's Disease Research, University of North Texas Health Science Center, Fort Worth, Tex.</aff><aff id='aff2'><sup>b</sup>Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Tex.</aff><aff id='aff3'><sup>c</sup>Department of Psychiatry, University of North Texas Health Science Center, Fort Worth, Tex.</aff><aff id='aff4'><sup>d</sup>Department of Internal Medicine, University of North Texas Health Science Center, Fort Worth, Tex.</aff><aff id='aff5'><sup>e</sup>Department of Neurology, F. Marie Hall Institute for Rural and Community Health, Texas Tech University Health Sciences Center, Lubbock, Tex.</aff><aff id='aff6'><sup>f</sup>Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Tex.</aff><aff id='aff7'><sup>g</sup>Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Tex.</aff><aff id='aff8'><sup>h</sup>Center for Neuroscience and Regenerative Medicine, Uniformed Services University of the Health Sciences, Bethesda, Md.</aff><aff id='aff9'><sup>i</sup>Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, N.C., USA</aff><author-notes><corresp id='cor1'>*Robert C. Barber, PhD, Institute for Aging and Alzheimer's Disease Research, University of North Texas Health Science Center, Fort Worth, TX 76107 (USA), Tel. +1 817 735 2506, E-Mail <email>robert.barber@unthsc.edu</email></corresp><fn id='other1' fn-type='other'><p>Investigators from the Texas Alzheimer's Research and Care Consortium: Baylor College of Medicine: Rachelle Doody, MD, PhD, Susan Rountree, MD, Valory Pavlik, PhD, Wen Chan, PhD, Paul Massman, PhD, Eveleen Darby, Tracy Evans, RN, and Aisha Khaleeq; Texas Tech University Health Science Center: Benjamin Williams, MD, Gregory Schrimsher, PhD, Andrew Dentino, MD, and Ronnie Orozco; University of North Texas Health Science Center: Thomas Fairchild, PhD, Janice Knebl, DO, Douglas Mains, and Lisa Alvarez; University of Texas Southwestern Medical Center: Perrie Adams, PhD, Roger Rosenberg, MD, Myron Weiner, MD, Mary Quiceno, MD, Joan Reisch, PhD, Doris Svetlik, Amy Werry, and Janet Smith; University of Texas Health Science Center – San Antonio: Donald Royall, MD, Raymond Palmer, PhD, and Marsha Polk.</p></fn></author-notes><pub-date pub-type='collection'><season>Jan-Dec</season><year>2012</year></pub-date><pub-date pub-type='epub'><day>29</day><month>8</month><year>2012</year></pub-date><pub-date pub-type='pmc-release'><day>29</day><month>8</month><year>2012</year></pub-date><volume>2</volume><issue>1</issue><fpage>353</fpage><lpage>360</lpage><permissions><copyright-statement>Copyright © 2012 by S. Karger AG, Basel</copyright-statement><copyright-year>2012</copyright-year><license license-type='open-access' xlink:href='http://creativecommons.org/licenses/by-nc-nd/3.0/'><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (<ext-link ext-link-type='uri' xlink:href='http://creativecommons.org/licenses/by-nc-nd/3.0/'>http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link>). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on <ext-link ext-link-type='uri' xlink:href='http://www.karger.com'>http://www.karger.com</ext-link> and the terms of this license are included in any shared versions.</license-p></license></permissions><abstract><sec><title>Background</title><p><s sid='2'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Granulocyte colony-stimulating factor (G-CSF) promotes the survival and function of neutrophils.</s><s sid='3'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> G-CSF is also a neurotrophic factor, increasing neuroplasticity and suppressing apoptosis.</s></p></sec><sec><title>Methods</title><p><s sid='4'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1><CoreSc2 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc2>We analyzed G-CSF levels in 197 patients with probable Alzheimer's disease (AD) and 203 cognitively normal controls (NCs) from a longitudinal study by the Texas Alzheimer's Research and Care Consortium (TARCC).</s><s sid='5'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Data were analyzed by regression with adjustment for age, education, gender and APOE4 status.</s></p></sec><sec><title>Results</title><p><s sid='6'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Serum G-CSF was significantly lower in AD patients than in NCs (β = −0.073; p = 0.008).</s><s sid='7'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> However, among AD patients, higher serum G-CSF was significantly associated with increased disease severity, as indicated by lower Mini-Mental State Examination scores (β = −0.178; p = 0.014) and higher scores on the global Clinical Dementia Rating (CDR) scale (β = 0.170; p = 0.018) and CDR Sum of Boxes (β = 0.157; p = 0.035).</s></p></sec><sec><title>Conclusions</title><p><s sid='8'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>G-CSF appears to have a complex relationship with AD pathogenesis and may reflect different pathophysiologic processes at different illness stages.</s></p></sec></abstract><kwd-group><title>Key Words</title><kwd>Granulocyte colony-stimulating factor</kwd><kwd>Alzheimer's disease</kwd><kwd>Inflammation</kwd><kwd>Serum proteins</kwd><kwd>Mini-Mental State Examination</kwd><kwd>Clinical Dementia Rating-Sum of Boxes</kwd></kwd-group><counts><table-count count='7'></table-count><ref-count count='18'></ref-count><page-count count='8'></page-count></counts></article-meta></front><body><sec id='sec1_1'><title>Introduction</title><p><s sid='9'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic growth factor that helps regulate the mobilization of bone marrow progenitor cells and promotes neuroprotection and neurogenesis [<xref rid='B1' ref-type='bibr'>1</xref>,<xref rid='B2' ref-type='bibr'>2</xref>].</s><s sid='10'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> G-CSF is produced by immune cells, particularly macrophages, as well as endothelial cells.</s><s sid='11'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Human G-CSF exists as a 174- or 180-amino-acid-long protein, with the 174-amino-acid form being more abundant and more active [<xref rid='B3' ref-type='bibr'>3</xref>].</s><s sid='12'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The G-CSF receptor is present on hematopoietic cells of the bone marrow and, when activated by G-CSF, initiates the proliferation and differentiation of progenitor cells into mature granulocytes [<xref rid='B1' ref-type='bibr'>1</xref>].</s><s sid='13'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The G-CSF receptor is also expressed by neurons in the brain and spinal cord, enabling G-CSF to act as a neurotrophic factor.</s><s sid='14'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In the central nervous system, G-CSF induces neurogenesis, counteracts apoptosis and increases neuroplasticity [<xref rid='B4' ref-type='bibr'>4</xref>,<xref rid='B5' ref-type='bibr'>5</xref>].</s></p><p><s sid='15'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>In rodent models of Alzheimer's disease (AD), G-CSF treatment decreased the amyloid burden in the brain [<xref rid='B6' ref-type='bibr'>6</xref>,<xref rid='B7' ref-type='bibr'>7</xref>], reversed cognitive impairment [<xref rid='B7' ref-type='bibr'>7</xref>] and reduced chronic inflammation [<xref rid='B8' ref-type='bibr'>8</xref>].</s><s sid='16'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In other studies, G-CSF administered to mice following ischemic injury has been shown to stimulate the proliferation of microglia [<xref rid='B9' ref-type='bibr'>9</xref>].</s></p><p><s sid='17'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>In the present study, we sought to determine whether the serum G-CSF level significantly differs between AD and control subjects and whether serum G-CSF levels are correlated with clinical measures of disease severity.</s></p></sec><sec sec-type='methods' id='sec1_2'><title>Methods</title><sec id='sec2_1'><title>Participants</title><p><s sid='18'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>Participants included 400 individuals (197 diagnosed with probable AD and 203 cognitively normal controls; NCs) enrolled in the Texas Alzheimer's Research and Care Consortium (TARCC) longitudinal research cohort.</s><s sid='19'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The methodology of the TARCC project has been described in detail elsewhere.</s><s sid='20'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Briefly, each participant completed an annual examination consisting of a medical examination, interview, blood draw and neuropsychological testing at one of the five TARCC sites.</s><s sid='21'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The TARCC core neuropsychological battery consists of commonly utilized instruments in AD clinical/research settings along with measures assessing global functioning, i.e. the Mini-Mental State Examination (MMSE) [<xref rid='B10' ref-type='bibr'>10</xref>] and the Clinical Dementia Rating (CDR) scale [<xref rid='B11' ref-type='bibr'>11</xref>].</s><s sid='22'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> These data were reviewed by each site's consensus committee, and a diagnosis was assigned according to NINCDS-ADRDA criteria [<xref rid='B12' ref-type='bibr'>12</xref>].</s><s sid='23'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> NCs were judged to be within normal limits on neuropsychological testing by consensus review.</s><s sid='24'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Participants with AD were largely in the mild-to-moderate range.</s><s sid='25'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The TARCC project has Institutional Review Board approval at all member institutions, and all participants and/or caregivers signed written informed consent documents.</s></p></sec><sec id='sec2_2'><title>Assays</title><p><s sid='26'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>Non-fasting samples were collected in serum-separating tubes during clinical evaluations, allowed to clot at room temperature for 1 h, centrifuged, aliquoted and stored at −80°C in polypropylene vials.</s><s sid='27'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Frozen samples were sent to Rules Based Medicine (<ext-link ext-link-type='uri' xlink:href='http://www.rulesbasedmedicine.com'>www.rulesbasedmedicine.com</ext-link>, Austin, Tex., USA), where they were thawed for assay without additional freeze-thaw cycles.</s><s sid='28'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Rules Based Medicine conducted a multiplex immunoassay via their human Multi-Analyte Profiling (human MAP) technology.</s><s sid='29'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Multiple proteins, including G-CSF, were quantified through multiplex fluorescent immunoassay utilizing colored microspheres with protein-specific antibodies.</s><s sid='30'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> For G-CSF, the least detectable dose was 5 pg/ml, inter-run coefficient of variation was &lt;10%, dynamic range was 1–5,000 pg/ml, overall spiked standard recovery for serum was 70% and cross-reactivity with other human MAP analytes was &lt;1%.</s><s sid='31'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Assays conducted by this company utilizing this platform, including TARCC data, have been published elsewhere [<xref rid='B13' ref-type='bibr'>13</xref>,<xref rid='B14' ref-type='bibr'>14</xref>].</s></p></sec><sec id='sec2_3'><title>Analyses</title><p><s sid='32'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Statistical analyses were conducted using SPSS version 19.0 (IBM).</s><s sid='33'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Unadjusted analyses were conducted by either t test for continuous or Mann-Whitney U test for categorical variables.</s><s sid='34'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Serum G-CSF levels were compared across diagnostic categories (AD vs. NC), and associations between G-CSF levels and disease severity (MMSE and CDR scores) were assessed by multivariate regression.</s><s sid='35'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> All regression models included age, sex, years of education, race and APOE4 carrier status as covariates.</s><s sid='36'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Statistical significance was declared for p values &lt;0.05.</s><s sid='37'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In follow-up analyses, the sample was stratified on APOE4 carrier status (–/– vs. –/+ and +/+), and the analyses described above were repeated.</s></p></sec></sec><sec sec-type='results' id='sec1_3'><title>Results</title><p><s sid='38'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Demographic characteristics of the study population are shown in table <xref rid='T1' ref-type='table'>1</xref>.</s><s sid='39'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Relative to controls, AD patients did not significantly differ with respect to sex, race or Hispanic ethnicity; however, they were significantly older (median age, 79 vs. 70 years; p &lt; 0.001), less educated (median years of education, 14 vs. 16; p &lt; 0.001) and more likely to carry one or more copies of the APOE ∊4 allele (APOE4 carriers, 13.7 vs. 2.5%; p &lt; 0.001).</s></p><p><s sid='40'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Median serum G-CSF levels were significantly lower in AD cases compared to controls (8.1 vs. 9.9 pg/ml, respectively; table <xref rid='T1' ref-type='table'>1</xref>).</s><s sid='41'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> G-CSF remained significantly associated with diagnostic category (β = −0.073; p = 0.008) following adjustment for age, sex, education and APOE status (table <xref rid='T2' ref-type='table'>2</xref>).</s><s sid='42'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> To test for residual confounding by the APOE4 allele, an analysis was run after stratification of the sample on APOE4 status.</s><s sid='43'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Serum G-CSF was not significantly associated with disease status in either the APOE4-positive or APOE4-negative group.</s><s sid='44'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> However, the p values were marginal (0.053 and 0.077 in APOE4-negative and APOE4-positive individuals, respectively), and the trends were consistent with those observed in the unstratified sample (data not presented).</s></p><p><s sid='45'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Among AD participants only (n = 197), higher serum G-CSF levels were negatively associated with lower (worse) scores on the MMSE (β = −0.178; p = 0.014; table <xref rid='T3' ref-type='table'>3</xref>) and positively associated with higher (worse) scores on the CDR Global (β = 0.170; p = 0.018; table <xref rid='T4' ref-type='table'>4</xref>) and CDR Sum of Boxes (β = 0.153; p = 0.035; table <xref rid='T5' ref-type='table'>5</xref>).</s></p><p><s sid='46'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>In post-hoc analyses, serum G-CSF levels were tested for association with individual neuropsychiatric test score by multivariate logistic regression.</s><s sid='47'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Serum G-CSF concentration was significantly associated with only digit span among AD participants and delayed logical memory among controls (table <xref rid='T6' ref-type='table'>6</xref>).</s><s sid='48'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In an attempt to resolve the impact of a number of key processes that have been shown to be important to AD pathology, we performed a set of stratified analyses.</s><s sid='49'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> First, we selected proteins that were representative of inflammation (C-reactive protein; CRP), coagulation (thrombopoietin; THP) and neurotrophic factors (brain derived neurotrophic factor; BDNF).</s><s sid='50'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Next, we stratified the participants based upon tertiles for each of these proteins.</s><s sid='51'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Finally, we evaluated the association between G-CSF and diagnostic status (AD vs. NC) for participants within each group.</s><s sid='52'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Serum G-CSF levels were significantly associated with diagnostic status for participants in the mid-tertile for THP and BDNF.</s><s sid='53'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> In contrast, G-CSF was associated with diagnostic status only for participants in the high-tertile for CRP (table <xref rid='T7' ref-type='table'>7</xref>).</s></p></sec><sec sec-type='discussion' id='sec1_4'><title>Discussion</title><p><s sid='54'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>In addition to hematopoietic functions, G-CSF has a number of neuroprotective effects.</s><s sid='55'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> With respect to AD, G-CSF increases the number of microglia, decreases β-amyloid deposition and reverses cognitive impairment in a mouse model [<xref rid='B15' ref-type='bibr'>15</xref>,<xref rid='B16' ref-type='bibr'>16</xref>].</s><s sid='56'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> In the present work, we sought to determine whether serum levels of G-CSF are associated with a diagnosis of AD or with disease severity among individuals with a diagnosis of probable AD.</s></p><p><s sid='57'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>In our primarily Caucasian cohort of individuals with a diagnosis of probable AD and NCs from Texas, we observed significantly lower serum levels of G-CSF protein among AD cases than controls.</s><s sid='58'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> This observation is in agreement with others [<xref rid='B17' ref-type='bibr'>17</xref>].</s><s sid='59'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> In follow-up analyses in the same cohort, we observed a significant positive association between serum G-CSF and disease severity, as measured by MMSE and CDR scores.</s></p><p><s sid='60'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>In agreement with the present study, Laske et al. [<xref rid='B17' ref-type='bibr'>17</xref>] reported lower plasma G-CSF levels in early AD subjects relative to controls.</s><s sid='61'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Furthermore, these authors observed that, among AD patients, plasma G-CSF showed a significant inverse correlation with amyloid-β (Aβ1–42) levels in cerebrospinal fluid.</s><s sid='62'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Our results in a larger cohort confirm part of this prior work as we observed a significantly lower level of serum G-CSF among AD patients, compared to NCs.</s><s sid='63'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> However, in contrast to Laske et al. [<xref rid='B17' ref-type='bibr'>17</xref>], we found that increased serum G-CSF was significantly associated with greater disease severity.</s><s sid='64'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> This difference between the present findings and those of Laske et al. [<xref rid='B17' ref-type='bibr'>17</xref>] may be due to statistical power and sample size issues.</s><s sid='65'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> While the previously published study analyzed samples from a total of 100 subjects (50 AD cases, 50 NCs), our results were based on 400 participants.</s><s sid='66'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Agreement in the direction of the association between G-CSF levels and increased disease severity among AD participants increases confidence in the results of the present study.</s></p><p><s sid='67'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Other researchers, including ourselves, have observed an impact of APOE4 status on associations between various biomarkers and disease status [<xref rid='B18' ref-type='bibr'>18</xref>].</s><s sid='68'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> However, in this instance, carriage of the APOE4 allele did not seem to influence the results.</s><s sid='69'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Although stratification of the sample negatively affected the tests by reducing the sample size and hence statistical power, all trends were in the same direction in both stratified and unstratified analyses.</s></p></sec><sec sec-type='conclusions' id='sec1_5'><title>Conclusions</title><p><s sid='70'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>In light of the neurotrophic and neuroprotective role of G-CSF, our results are consistent with the hypothesis that reduced G-CSF abundance contributes to AD pathology.</s><s sid='71'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> Taken together, these observations raise the possibility that G-CSF is dysregulated early in the disease process and that the elevation in G-CSF observed in more advanced disease may represent a compensatory response.</s><s sid='72'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> Future work by TARCC scientists will investigate this possibility through the analysis of longitudinal samples collected from the same participants over several years.</s><s sid='73'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> These findings have implications for the design of clinical trials of G-CSF for the prevention or treatment of AD.</s></p></sec><sec id='sec1_6'><title>Disclosure Statement</title><p>The authors have no actual or potential conflict of interest.</p></sec></body><back><ack><title>Acknowledgements</title><p>This study was made possible by the Texas Alzheimer's Research and Care Consortium (TARCC) funded by the state of Texas through the Texas Council on Alzheimer's Disease and Related Disorders. Investigators at the University of Texas Southwestern Medical Center at Dallas also acknowledge support from the UTSW Alzheimer's Disease Center (NIH, NIA grant P30AG12300).</p></ack><ref-list><title>References</title><ref id='B1'><label>1</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Thomas</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Link</surname><given-names>DC</given-names></name></person-group><article-title>Mechanisms of mobilization of hematopoietic progenitors with granulocyte colony-stimulating factor</article-title><source>Curr Opin Hematol</source><year>2002</year><volume>9</volume><fpage>183</fpage><lpage>189</lpage><pub-id pub-id-type='pmid'>11953662</pub-id></element-citation></ref><ref id='B2'><label>2</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Schneider</surname><given-names>A</given-names></name><name><surname>Kuhn</surname><given-names>HG</given-names></name><name><surname>Schäbitz</surname><given-names>WR</given-names></name></person-group><article-title>A role for G-CSF (granulocyte-colony stimulating factor) in the central nervous system</article-title><source>Cell Cycle</source><year>2005</year><volume>4</volume><fpage>1753</fpage><lpage>1757</lpage><pub-id pub-id-type='pmid'>16258290</pub-id></element-citation></ref><ref id='B3'><label>3</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Asano</surname><given-names>S</given-names></name></person-group><article-title>Human granulocyte colony-stimulating factor: its basic aspects and clinical applications</article-title><source>Am J Pediatr Hematol Oncol</source><year>1991</year><volume>13</volume><fpage>400</fpage><lpage>413</lpage><pub-id pub-id-type='pmid'>1723850</pub-id></element-citation></ref><ref id='B4'><label>4</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Schneider</surname><given-names>A</given-names></name><name><surname>Krüger</surname><given-names>C</given-names></name><name><surname>Steigleder</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis</article-title><source>J Clin Invest</source><year>2005</year><volume>115</volume><fpage>2083</fpage><lpage>2098</lpage><pub-id pub-id-type='pmid'>16007267</pub-id></element-citation></ref><ref id='B5'><label>5</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Pitzer</surname><given-names>C</given-names></name><name><surname>Krüger</surname><given-names>C</given-names></name><name><surname>Plaas</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis</article-title><source>Brain</source><year>2008</year><volume>131</volume><fpage>3335</fpage><lpage>3347</lpage><pub-id pub-id-type='pmid'>18835867</pub-id></element-citation></ref><ref id='B6'><label>6</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Gonzalez-Toledo</surname><given-names>ME</given-names></name><name><surname>Piao</surname><given-names>CS</given-names></name><etal></etal></person-group><article-title>Stem cell factor and granulocyte-colony stimulating factor reduce beta-amyloid deposits in the brains of APP/PS1 transgenic mice</article-title><source>Alzheimers Res Ther</source><year>2011</year><volume>3</volume><fpage>8</fpage><pub-id pub-id-type='pmid'>21406112</pub-id></element-citation></ref><ref id='B7'><label>7</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Sanchez-Ramos</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>S</given-names></name><name><surname>Sava</surname><given-names>V</given-names></name><etal></etal></person-group><article-title>Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice</article-title><source>Neuroscience</source><year>2009</year><volume>163</volume><fpage>55</fpage><lpage>72</lpage><pub-id pub-id-type='pmid'>19500657</pub-id></element-citation></ref><ref id='B8'><label>8</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>CX</given-names></name><name><surname>Feng</surname><given-names>JB</given-names></name><etal></etal></person-group><article-title>Granulocyte colony-stimulating factor attenuates chronic neuroinflammation in the brain of amyloid precursor protein transgenic mice: an Alzheimer's disease mouse model</article-title><source>J Int Med Res</source><year>2010</year><volume>38</volume><fpage>1305</fpage><lpage>1312</lpage><pub-id pub-id-type='pmid'>20926003</pub-id></element-citation></ref><ref id='B9'><label>9</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Bartolini</surname><given-names>A</given-names></name><name><surname>Vigliani</surname><given-names>MC</given-names></name><name><surname>Magrassi</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>G-CSF administration to adult mice stimulates the proliferation of microglia but does not modify the outcome of ischemic injury</article-title><source>Neurobiol Dis</source><year>2011</year><volume>41</volume><fpage>640</fpage><lpage>649</lpage><pub-id pub-id-type='pmid'>21111821</pub-id></element-citation></ref><ref id='B10'><label>10</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Folstein</surname><given-names>MF</given-names></name><name><surname>Folstein</surname><given-names>SE</given-names></name><name><surname>McHugh</surname><given-names>PR</given-names></name></person-group><article-title>‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician</article-title><source>J Psychiatr Res</source><year>1975</year><volume>12</volume><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type='pmid'>1202204</pub-id></element-citation></ref><ref id='B11'><label>11</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Morris</surname><given-names>JC</given-names></name></person-group><article-title>The Clinical Dementia Rating (CDR): current version and scoring rules</article-title><source>Neurology</source><year>1993</year><volume>43</volume><fpage>2412</fpage><lpage>2414</lpage><pub-id pub-id-type='pmid'>8232972</pub-id></element-citation></ref><ref id='B12'><label>12</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>McKhann</surname><given-names>G</given-names></name><name><surname>Drachman</surname><given-names>D</given-names></name><name><surname>Folstein</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease</article-title><source>Neurology</source><year>1984</year><volume>34</volume><fpage>939</fpage><lpage>944</lpage><pub-id pub-id-type='pmid'>6610841</pub-id></element-citation></ref><ref id='B13'><label>13</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Simón-Sánchez</surname><given-names>J</given-names></name><name><surname>Singleton</surname><given-names>A</given-names></name></person-group><article-title>Genome-wide association studies in neurological disorders</article-title><source>Lancet Neurol</source><year>2008</year><volume>7</volume><fpage>1067</fpage><lpage>1072</lpage><pub-id pub-id-type='pmid'>18940696</pub-id></element-citation></ref><ref id='B14'><label>14</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>O’Bryant</surname><given-names>SE</given-names></name><name><surname>Xiao</surname><given-names>G</given-names></name><name><surname>Barber</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>A serum protein-based algorithm for the detection of Alzheimer disease</article-title><source>Arch Neurol</source><year>2010</year><volume>67</volume><fpage>1077</fpage><lpage>1081</lpage><pub-id pub-id-type='pmid'>20837851</pub-id></element-citation></ref><ref id='B15'><label>15</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Kannengiesser</surname><given-names>K</given-names></name><name><surname>Maaser</surname><given-names>C</given-names></name><name><surname>Kucharzik</surname><given-names>T</given-names></name></person-group><article-title>Molecular pathogenesis of inflammatory bowel disease: relevance for novel therapies</article-title><source>Per Med</source><year>2008</year><volume>5</volume><fpage>609</fpage><lpage>626</lpage></element-citation></ref><ref id='B16'><label>16</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Borel</surname><given-names>C</given-names></name><name><surname>Antonarakis</surname><given-names>SE</given-names></name></person-group><article-title>Functional genetic variation of human miRNAs and phenotypic consequences</article-title><source>Mamm Genome</source><year>2008</year><volume>19</volume><fpage>503</fpage><lpage>509</lpage><pub-id pub-id-type='pmid'>18787897</pub-id></element-citation></ref><ref id='B17'><label>17</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Laske</surname><given-names>C</given-names></name><name><surname>Stellos</surname><given-names>K</given-names></name><name><surname>Stransky</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Decreased plasma levels of granulocyte-colony stimulating factor (G-CSF) in patients with early Alzheimer's disease</article-title><source>J Alzheimers Dis</source><year>2009</year><volume>17</volume><fpage>115</fpage><lpage>123</lpage><pub-id pub-id-type='pmid'>19494436</pub-id></element-citation></ref><ref id='B18'><label>18</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Leoni</surname><given-names>V</given-names></name></person-group><article-title>The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease</article-title><source>Clin Chem Lab Med</source><year>2011</year><volume>49</volume><fpage>375</fpage><lpage>383</lpage><pub-id pub-id-type='pmid'>21388338</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap orientation='portrait' id='T1' position='float'><label>Table 1</label><caption><p>Demographic information of the 400 participants in the TARCC longitudinal research cohort</p></caption><table rules='groups' frame='hsides'><thead><tr valign='top'><th colspan='1' rowspan='1' align='left'>Variable</th><th colspan='1' rowspan='1' align='left'>AD (n = 197)</th><th colspan='1' rowspan='1' align='left'>NC (n = 203)</th><th colspan='1' rowspan='1' align='left'>p value</th></tr></thead><tbody><tr valign='top'><td colspan='1' rowspan='1' align='left'>Male gender</td><td colspan='1' rowspan='1' char='.' align='char'>34.5%</td><td colspan='1' rowspan='1' char='.' align='char'>32.0%</td><td colspan='1' rowspan='1' char='.' align='char'>0.67</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Age, years</td><td colspan='1' rowspan='1' align='left'></td><td colspan='1' rowspan='1' align='left'></td><td colspan='1' rowspan='1' align='left'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>  Median</td><td colspan='1' rowspan='1' char='.' align='char'>79.0</td><td colspan='1' rowspan='1' char='.' align='char'>70.0</td><td colspan='1' rowspan='1' align='left'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>  Range</td><td colspan='1' rowspan='1' char='.' align='char'>57.0–94.0</td><td colspan='1' rowspan='1' char='.' align='char'>52.0–90.0</td><td colspan='1' rowspan='1' align='left'>&lt;0.0001</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Education, years</td><td colspan='1' rowspan='1' align='left'></td><td colspan='1' rowspan='1' align='left'></td><td colspan='1' rowspan='1' align='left'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>  Median</td><td colspan='1' rowspan='1' char='.' align='char'>14</td><td colspan='1' rowspan='1' char='.' align='char'>16</td><td colspan='1' rowspan='1' align='left'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>  Range</td><td colspan='1' rowspan='1' char='.' align='char'>0–22</td><td colspan='1' rowspan='1' char='.' align='char'>10–25</td><td colspan='1' rowspan='1' align='left'>&lt;0.0001</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>APOE4 status</td><td colspan='1' rowspan='1' align='left'></td><td colspan='1' rowspan='1' align='left'></td><td colspan='1' rowspan='1' align='left'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>−/−</td><td colspan='1' rowspan='1' char='.' align='char'>71</td><td colspan='1' rowspan='1' char='.' align='char'>147</td><td colspan='1' rowspan='1' align='left'>&lt;0.0001</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>−/+</td><td colspan='1' rowspan='1' char='.' align='char'>83</td><td colspan='1' rowspan='1' char='.' align='char'>48</td><td colspan='1' rowspan='1' align='left'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>+/+</td><td colspan='1' rowspan='1' char='.' align='char'>27</td><td colspan='1' rowspan='1' char='.' align='char'>5</td><td colspan='1' rowspan='1' align='left'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Unknown</td><td colspan='1' rowspan='1' char='.' align='char'>16</td><td colspan='1' rowspan='1' char='.' align='char'>3</td><td colspan='1' rowspan='1' align='left'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Hispanic ethnicity</td><td colspan='1' rowspan='1' char='.' align='char'>3.6%</td><td colspan='1' rowspan='1' char='.' align='char'>5.4%</td><td colspan='1' rowspan='1' char='.' align='char'>0.47</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Race</td><td colspan='1' rowspan='1' align='left'></td><td colspan='1' rowspan='1' align='left'></td><td colspan='1' rowspan='1' align='left'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>  White</td><td colspan='1' rowspan='1' char='.' align='char'>187</td><td colspan='1' rowspan='1' char='.' align='char'>190</td><td colspan='1' rowspan='1' align='left'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Non-White</td><td colspan='1' rowspan='1' char='.' align='char'>10</td><td colspan='1' rowspan='1' char='.' align='char'>13</td><td colspan='1' rowspan='1' char='.' align='char'>0.67</td></tr></tbody></table></table-wrap><table-wrap orientation='portrait' id='T2' position='float'><label>Table 2</label><caption><p>Odds ratio for disease status following adjustment for multiple factors as determined by multivariate logistic regression</p></caption><table rules='groups' frame='hsides'><thead><tr valign='top'><th colspan='1' rowspan='1' align='left'>Variable</th><th colspan='1' rowspan='1' align='left'>B</th><th colspan='1' rowspan='1' align='left'>SE</th><th colspan='1' rowspan='1' align='left'>Exp(B)</th><th colspan='2' rowspan='1' align='left'>95% CI Exp(B)<hr></hr></th><th colspan='1' rowspan='1' align='left'>p value</th></tr><tr><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'>lower</th><th colspan='1' rowspan='1' align='left'>upper</th><th colspan='1' rowspan='1' align='left'></th></tr></thead><tbody><tr valign='top'><td colspan='1' rowspan='1' align='left'>Age</td><td colspan='1' rowspan='1' char='.' align='char'>0.088</td><td colspan='1' rowspan='1' char='.' align='char'>0.014</td><td colspan='1' rowspan='1' char='.' align='char'>1.092</td><td colspan='1' rowspan='1' char='.' align='char'>1.061</td><td colspan='1' rowspan='1' char='.' align='char'>1.123</td><td colspan='1' rowspan='1' align='left'>&lt;0.001</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Sex</td><td colspan='1' rowspan='1' align='left'>−0.434</td><td colspan='1' rowspan='1' char='.' align='char'>0.263</td><td colspan='1' rowspan='1' char='.' align='char'>0.648</td><td colspan='1' rowspan='1' char='.' align='char'>0.387</td><td colspan='1' rowspan='1' char='.' align='char'>1.085</td><td colspan='1' rowspan='1' char='.' align='char'>0.099</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Education</td><td colspan='1' rowspan='1' char='.' align='char'>0.162</td><td colspan='1' rowspan='1' char='.' align='char'>0.043</td><td colspan='1' rowspan='1' char='.' align='char'>0.851</td><td colspan='1' rowspan='1' char='.' align='char'>0.781</td><td colspan='1' rowspan='1' char='.' align='char'>0.926</td><td colspan='1' rowspan='1' align='left'>&lt;0.001</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>APOE4</td><td colspan='1' rowspan='1' char='.' align='char'>1.623</td><td colspan='1' rowspan='1' char='.' align='char'>0.255</td><td colspan='1' rowspan='1' char='.' align='char'>5.066</td><td colspan='1' rowspan='1' char='.' align='char'>3.074</td><td colspan='1' rowspan='1' char='.' align='char'>8.349</td><td colspan='1' rowspan='1' align='left'>&lt;0.001</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>G-CSF</td><td colspan='1' rowspan='1' align='left'>−0.073</td><td colspan='1' rowspan='1' char='.' align='char'>0.028</td><td colspan='1' rowspan='1' char='.' align='char'>0.930</td><td colspan='1' rowspan='1' char='.' align='char'>0.881</td><td colspan='1' rowspan='1' char='.' align='char'>0.981</td><td colspan='1' rowspan='1' char='.' align='char'>0.008</td></tr></tbody></table><table-wrap-foot><fn><p>Age, education and G-CSF concentration were analyzed as continuous variables. Odds ratios are for each additional year of age and year of education.</p></fn></table-wrap-foot></table-wrap><table-wrap orientation='portrait' id='T3' position='float'><label>Table 3</label><caption><p>Multivariate logistic regression for MMSE scores of participants in the TARCC longitudinal cohort with a diagnosis of probable AD</p></caption><table rules='groups' frame='hsides'><thead><tr valign='top'><th colspan='1' rowspan='1' align='left'>Variable</th><th colspan='2' rowspan='1' align='left'>Unstandardized coefficients<hr></hr></th><th colspan='1' rowspan='1' align='left'>Standardized coefficient</th><th colspan='1' rowspan='1' align='left'>t</th><th colspan='1' rowspan='1' align='left'>p value</th></tr><tr><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'>B</th><th colspan='1' rowspan='1' align='left'>Std error</th><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'></th></tr></thead><tbody><tr><td colspan='1' rowspan='1' align='left'>Age</td><td colspan='1' rowspan='1' char='.' align='char'>0.045</td><td colspan='1' rowspan='1' char='.' align='char'>0.056</td><td colspan='1' rowspan='1' char='.' align='char'>0.059</td><td colspan='1' rowspan='1' char='.' align='char'>0.796</td><td colspan='1' rowspan='1' char='.' align='char'>0.427</td></tr><tr><td colspan='1' rowspan='1' align='left'>Sex</td><td colspan='1' rowspan='1' char='.' align='char'>0.128</td><td colspan='1' rowspan='1' char='.' align='char'>0.973</td><td colspan='1' rowspan='1' char='.' align='char'>0.010</td><td colspan='1' rowspan='1' char='.' align='char'>0.132</td><td colspan='1' rowspan='1' char='.' align='char'>0.895</td></tr><tr><td colspan='1' rowspan='1' align='left'>Education</td><td colspan='1' rowspan='1' char='.' align='char'>0.098</td><td colspan='1' rowspan='1' char='.' align='char'>0.140</td><td colspan='1' rowspan='1' char='.' align='char'>0.051</td><td colspan='1' rowspan='1' char='.' align='char'>0.701</td><td colspan='1' rowspan='1' char='.' align='char'>0.484</td></tr><tr><td colspan='1' rowspan='1' align='left'>APOE4</td><td colspan='1' rowspan='1' align='left'>−0.710</td><td colspan='1' rowspan='1' char='.' align='char'>0.932</td><td colspan='1' rowspan='1' align='left'>−0.056</td><td colspan='1' rowspan='1' align='left'>−0.761</td><td colspan='1' rowspan='1' char='.' align='char'>0.447</td></tr><tr><td colspan='1' rowspan='1' align='left'>G-CSF</td><td colspan='1' rowspan='1' char='.' align='char'>−0.256</td><td colspan='1' rowspan='1' char='.' align='char'>0.104</td><td colspan='1' rowspan='1' char='.' align='char'>−0.178</td><td colspan='1' rowspan='1' char='.' align='char'>−2.469</td><td colspan='1' rowspan='1' char='.' align='char'>0.014</td></tr></tbody></table><table-wrap-foot><fn><p>Age, education and G-CSF were analyzed as continuous variables. APOE4 status was determined by the carriage of at least one APOE4 allele.</p></fn></table-wrap-foot></table-wrap><table-wrap orientation='portrait' id='T4' position='float'><label>Table 4</label><caption><p>Multivariate logistic regression for global CDR scores of participants in the TARCC longitudinal cohort with a diagnosis of probable AD</p></caption><table rules='groups' frame='hsides'><thead><tr valign='top'><th colspan='1' rowspan='1' align='left'>Variable</th><th colspan='2' rowspan='1' align='left'>Unstandardized coefficients<hr></hr></th><th colspan='1' rowspan='1' align='left'>Standardized coefficient β</th><th colspan='1' rowspan='1' align='left'>t</th><th colspan='1' rowspan='1' align='left'>p value</th></tr><tr><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'>B</th><th colspan='1' rowspan='1' align='left'>Std error</th><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'></th></tr></thead><tbody><tr valign='top'><td colspan='1' rowspan='1' align='left'>Age</td><td colspan='1' rowspan='1' char='.' align='char'>0.011</td><td colspan='1' rowspan='1' char='.' align='char'>0.007</td><td colspan='1' rowspan='1' char='.' align='char'>0.126</td><td colspan='1' rowspan='1' char='.' align='char'>1.701</td><td colspan='1' rowspan='1' char='.' align='char'>0.091</td></tr><tr><td colspan='1' rowspan='1' align='left'>Sex</td><td colspan='1' rowspan='1' char='.' align='char'>0.081</td><td colspan='1' rowspan='1' char='.' align='char'>0.116</td><td colspan='1' rowspan='1' char='.' align='char'>0.052</td><td colspan='1' rowspan='1' char='.' align='char'>0.704</td><td colspan='1' rowspan='1' char='.' align='char'>0.482</td></tr><tr><td colspan='1' rowspan='1' align='left'>Education</td><td colspan='1' rowspan='1' align='left'>−0.009</td><td colspan='1' rowspan='1' char='.' align='char'>0.016</td><td colspan='1' rowspan='1' align='left'>−0.038</td><td colspan='1' rowspan='1' align='left'>−0.531</td><td colspan='1' rowspan='1' char='.' align='char'>0.596</td></tr><tr><td colspan='1' rowspan='1' align='left'>APOE4</td><td colspan='1' rowspan='1' char='.' align='char'>0.001</td><td colspan='1' rowspan='1' char='.' align='char'>0.111</td><td colspan='1' rowspan='1' char='.' align='char'>0.001</td><td colspan='1' rowspan='1' char='.' align='char'>0.013</td><td colspan='1' rowspan='1' char='.' align='char'>0.990</td></tr><tr><td colspan='1' rowspan='1' align='left'>G-CSF</td><td colspan='1' rowspan='1' char='.' align='char'>0.030</td><td colspan='1' rowspan='1' char='.' align='char'>0.012</td><td colspan='1' rowspan='1' char='.' align='char'>0.170</td><td colspan='1' rowspan='1' char='.' align='char'>2.379</td><td colspan='1' rowspan='1' char='.' align='char'>0.018</td></tr></tbody></table><table-wrap-foot><fn><p>Age, education and G-CSF were analyzed as continuous variables. APOE4 status was determined by the carriage of at least one APOE4 allele.</p></fn></table-wrap-foot></table-wrap><table-wrap orientation='portrait' id='T5' position='float'><label>Table 5</label><caption><p>Multivariate logistic regression for CDR-Sum of Boxes scores of participants in the TARCC longitudinal cohort with a diagnosis of probable AD</p></caption><table rules='groups' frame='hsides'><thead><tr valign='top'><th colspan='1' rowspan='1' align='left'>Variable</th><th colspan='2' rowspan='1' align='left'>Unstandardized coefficients<hr></hr></th><th colspan='1' rowspan='1' align='left'>Standardized coefficient β</th><th colspan='1' rowspan='1' align='left'>t</th><th colspan='1' rowspan='1' align='left'>p value</th></tr><tr><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'>B</th><th colspan='1' rowspan='1' align='left'>Std error</th><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'></th></tr></thead><tbody><tr valign='top'><td colspan='1' rowspan='1' align='left'>Age</td><td colspan='1' rowspan='1' char='.' align='char'>0.058</td><td colspan='1' rowspan='1' char='.' align='char'>0.040</td><td colspan='1' rowspan='1' char='.' align='char'>0.109</td><td colspan='1' rowspan='1' char='.' align='char'>1.462</td><td colspan='1' rowspan='1' char='.' align='char'>0.145</td></tr><tr><td colspan='1' rowspan='1' align='left'>Sex</td><td colspan='1' rowspan='1' char='.' align='char'>0.376</td><td colspan='1' rowspan='1' char='.' align='char'>0.686</td><td colspan='1' rowspan='1' char='.' align='char'>0.040</td><td colspan='1' rowspan='1' char='.' align='char'>0.549</td><td colspan='1' rowspan='1' char='.' align='char'>0.584</td></tr><tr><td colspan='1' rowspan='1' align='left'>Education</td><td colspan='1' rowspan='1' align='left'>−0.072</td><td colspan='1' rowspan='1' char='.' align='char'>0.097</td><td colspan='1' rowspan='1' align='left'>−0.054</td><td colspan='1' rowspan='1' align='left'>−0.745</td><td colspan='1' rowspan='1' char='.' align='char'>0.457</td></tr><tr><td colspan='1' rowspan='1' align='left'>APOE4</td><td colspan='1' rowspan='1' char='.' align='char'>0.083</td><td colspan='1' rowspan='1' char='.' align='char'>0.661</td><td colspan='1' rowspan='1' char='.' align='char'>0.009</td><td colspan='1' rowspan='1' char='.' align='char'>0.126</td><td colspan='1' rowspan='1' char='.' align='char'>0.900</td></tr><tr><td colspan='1' rowspan='1' align='left'>G-CSF</td><td colspan='1' rowspan='1' char='.' align='char'>0.157</td><td colspan='1' rowspan='1' char='.' align='char'>0.074</td><td colspan='1' rowspan='1' char='.' align='char'>0.153</td><td colspan='1' rowspan='1' char='.' align='char'>2.126</td><td colspan='1' rowspan='1' char='.' align='char'>0.035</td></tr></tbody></table><table-wrap-foot><fn><p>Age, education and G-CSF were analyzed as continuous variables. APOE4 status was determined by the carriage of at least one APOE4 allele.</p></fn></table-wrap-foot></table-wrap><table-wrap orientation='portrait' id='T6' position='float'><label>Table 6</label><caption><p>Multivariate logistic regression for association between serum G-CSF levels and neuropsychological test scores, following adjustment for age, gender, years of education and APOE4 status</p></caption><table rules='groups' frame='hsides'><thead><tr valign='top'><th colspan='1' rowspan='1' align='left'>Variables</th><th colspan='2' rowspan='1' align='left'>AD G-CSF<hr></hr></th><th colspan='2' rowspan='1' align='left'>NC G-CSF<hr></hr></th></tr><tr><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'>Standardized β</th><th colspan='1' rowspan='1' align='left'>p value</th><th colspan='1' rowspan='1' align='left'>Standardized β</th><th colspan='1' rowspan='1' align='left'>p value</th></tr></thead><tbody><tr><td colspan='1' rowspan='1' align='left'>COWAT</td><td colspan='1' rowspan='1' char='.' align='char'>0.028</td><td colspan='1' rowspan='1' char='.' align='char'>0.720</td><td colspan='1' rowspan='1' align='left'>−0.053</td><td colspan='1' rowspan='1' char='.' align='char'>0.463</td></tr><tr><td colspan='1' rowspan='1' align='left'>Boston 60</td><td colspan='1' rowspan='1' char='.' align='char'>0.025</td><td colspan='1' rowspan='1' char='.' align='char'>0.735</td><td colspan='1' rowspan='1' char='.' align='char'>0.011</td><td colspan='1' rowspan='1' char='.' align='char'>0.864</td></tr><tr><td colspan='1' rowspan='1' align='left'>AMNART</td><td colspan='1' rowspan='1' align='left'>−0.094</td><td colspan='1' rowspan='1' char='.' align='char'>0.146</td><td colspan='1' rowspan='1' align='left'>−0.068</td><td colspan='1' rowspan='1' char='.' align='char'>0.313</td></tr><tr><td colspan='1' rowspan='1' align='left'>Trails A</td><td colspan='1' rowspan='1' align='left'>−0.095</td><td colspan='1' rowspan='1' char='.' align='char'>0.248</td><td colspan='1' rowspan='1' align='left'>−0.099</td><td colspan='1' rowspan='1' char='.' align='char'>0.206</td></tr><tr><td colspan='1' rowspan='1' align='left'>Trails B</td><td colspan='1' rowspan='1' char='.' align='char'>0.042</td><td colspan='1' rowspan='1' char='.' align='char'>0.659</td><td colspan='1' rowspan='1' char='.' align='char'>0.092</td><td colspan='1' rowspan='1' char='.' align='char'>0.240</td></tr><tr><td colspan='1' rowspan='1' align='left'>Estimated VIQ</td><td colspan='1' rowspan='1' align='left'>−0.067</td><td colspan='1' rowspan='1' char='.' align='char'>0.248</td><td colspan='1' rowspan='1' align='left'>−0.081</td><td colspan='1' rowspan='1' char='.' align='char'>0.160</td></tr><tr><td colspan='1' rowspan='1' align='left'>Digit Span Total</td><td colspan='1' rowspan='1' align='left'>−0.180</td><td colspan='1' rowspan='1' char='.' align='char'>0.011<xref rid='T6F1' ref-type='table-fn'>*</xref></td><td colspan='1' rowspan='1' align='left'>−0.003</td><td colspan='1' rowspan='1' char='.' align='char'>0.963</td></tr><tr><td colspan='1' rowspan='1' align='left'>LM I</td><td colspan='1' rowspan='1' align='left'>−0.006</td><td colspan='1' rowspan='1' char='.' align='char'>0.944</td><td colspan='1' rowspan='1' char='.' align='char'>0.158</td><td colspan='1' rowspan='1' char='.' align='char'>0.044</td></tr><tr><td colspan='1' rowspan='1' align='left'>LM II</td><td colspan='1' rowspan='1' align='left'>−0.085</td><td colspan='1' rowspan='1' char='.' align='char'>0.256</td><td colspan='1' rowspan='1' char='.' align='char'>0.180</td><td colspan='1' rowspan='1' char='.' align='char'>0.022<xref rid='T6F1' ref-type='table-fn'>*</xref></td></tr><tr><td colspan='1' rowspan='1' align='left'>VR I</td><td colspan='1' rowspan='1' align='left'>−0.047</td><td colspan='1' rowspan='1' char='.' align='char'>0.548</td><td colspan='1' rowspan='1' char='.' align='char'>0.021</td><td colspan='1' rowspan='1' char='.' align='char'>0.786</td></tr><tr><td colspan='1' rowspan='1' align='left'>VR II</td><td colspan='1' rowspan='1' align='left'>−0.073</td><td colspan='1' rowspan='1' char='.' align='char'>0.319</td><td colspan='1' rowspan='1' char='.' align='char'>0.059</td><td colspan='1' rowspan='1' char='.' align='char'>0.440</td></tr></tbody></table><table-wrap-foot><fn><p>Estimated VIQ = Estimated premorbid intelligence quotient; LM 1 = immediate logical memory;</p><p>LM II = delayed logical memory; VR I = immediate visual recall; VR II = delayed visual recall.</p></fn><fn id='T6F1'><p>* Significant after Bonferroni adjustment for multiple testing.</p></fn></table-wrap-foot></table-wrap><table-wrap orientation='portrait' id='T7' position='float'><label>Table 7</label><caption><p>Results for G-CSF from multivariate logistic regression analysis of G-CSF and MMSE scores among AD patients following stratification into tertiles on brain-derived neurotrophic factor (BDNF), C-reactive protein (CRP) and thrombopoietin</p></caption><table rules='groups' frame='hsides'><thead><tr valign='top'><th colspan='1' rowspan='1' align='left'>Protein</th><th colspan='1' rowspan='1' align='left'>Tertile</th><th colspan='2' rowspan='1' align='left'>Unstandardized coefficients<hr></hr></th><th colspan='1' rowspan='1' align='left'>Standardized coefficient</th><th colspan='1' rowspan='1' align='left'>t</th><th colspan='1' rowspan='1' align='left'>p value</th></tr><tr><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'>B</th><th colspan='1' rowspan='1' align='left'>Std error</th><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'></th></tr></thead><tbody><tr><td colspan='1' rowspan='1' align='left'>Thrombopoietin</td><td colspan='1' rowspan='1' align='left'>Low</td><td colspan='1' rowspan='1' char='.' align='char'>0.024</td><td colspan='1' rowspan='1' char='.' align='char'>0.182</td><td colspan='1' rowspan='1' char='.' align='char'>0.018</td><td colspan='1' rowspan='1' char='.' align='char'>0.132</td><td colspan='1' rowspan='1' char='.' align='char'>0.896</td></tr><tr><td colspan='1' rowspan='1' align='left'></td><td colspan='1' rowspan='1' align='left'>Medium</td><td colspan='1' rowspan='1' align='left'>−0.662</td><td colspan='1' rowspan='1' char='.' align='char'>0.177</td><td colspan='1' rowspan='1' align='left'>−0.440</td><td colspan='1' rowspan='1' align='left'>−3.739</td><td colspan='1' rowspan='1' align='left'>&lt;0.001<xref rid='T7F2' ref-type='table-fn'>**</xref></td></tr><tr><td colspan='1' rowspan='1' align='left'></td><td colspan='1' rowspan='1' align='left'>High</td><td colspan='1' rowspan='1' align='left'>−0.252</td><td colspan='1' rowspan='1' char='.' align='char'>0.207</td><td colspan='1' rowspan='1' align='left'>−0.159</td><td colspan='1' rowspan='1' align='left'>−1.218</td><td colspan='1' rowspan='1' char='.' align='char'>0.228</td></tr><tr><td colspan='1' rowspan='1' align='left'>BDNF</td><td colspan='1' rowspan='1' align='left'>Low</td><td colspan='1' rowspan='1' align='left'>−0.280</td><td colspan='1' rowspan='1' char='.' align='char'>0.184</td><td colspan='1' rowspan='1' align='left'>−0.182</td><td colspan='1' rowspan='1' align='left'>−1.515</td><td colspan='1' rowspan='1' char='.' align='char'>0.135</td></tr><tr><td colspan='1' rowspan='1' align='left'></td><td colspan='1' rowspan='1' align='left'>Medium</td><td colspan='1' rowspan='1' align='left'>−0.423</td><td colspan='1' rowspan='1' char='.' align='char'>0.168</td><td colspan='1' rowspan='1' align='left'>−0.338</td><td colspan='1' rowspan='1' align='left'>−2.524</td><td colspan='1' rowspan='1' char='.' align='char'>0.015<xref rid='T7F1' ref-type='table-fn'>*</xref></td></tr><tr><td colspan='1' rowspan='1' align='left'></td><td colspan='1' rowspan='1' align='left'>High</td><td colspan='1' rowspan='1' align='left'>−0.132</td><td colspan='1' rowspan='1' char='.' align='char'>0.186</td><td colspan='1' rowspan='1' char='.' align='char'>0.086</td><td colspan='1' rowspan='1' char='.' align='char'>0.712</td><td colspan='1' rowspan='1' char='.' align='char'>0.479</td></tr><tr><td colspan='1' rowspan='1' align='left'>CRP</td><td colspan='1' rowspan='1' align='left'>Low</td><td colspan='1' rowspan='1' align='left'>−0.121</td><td colspan='1' rowspan='1' char='.' align='char'>0.168</td><td colspan='1' rowspan='1' align='left'>−0.093</td><td colspan='1' rowspan='1' align='left'>−0.720</td><td colspan='1' rowspan='1' char='.' align='char'>0.475</td></tr><tr><td colspan='1' rowspan='1' align='left'></td><td colspan='1' rowspan='1' align='left'>Medium</td><td colspan='1' rowspan='1' align='left'>−0.069</td><td colspan='1' rowspan='1' char='.' align='char'>0.174</td><td colspan='1' rowspan='1' align='left'>−0.051</td><td colspan='1' rowspan='1' align='left'>−0.399</td><td colspan='1' rowspan='1' char='.' align='char'>0.692</td></tr><tr><td colspan='1' rowspan='1' align='left'></td><td colspan='1' rowspan='1' align='left'>High</td><td colspan='1' rowspan='1' align='left'>−0.722</td><td colspan='1' rowspan='1' char='.' align='char'>0.195</td><td colspan='1' rowspan='1' align='left'>−0.450</td><td colspan='1' rowspan='1' align='left'>−3.699</td><td colspan='1' rowspan='1' align='left'>&lt;0.001<xref rid='T7F2' ref-type='table-fn'>**</xref></td></tr></tbody></table><table-wrap-foot><fn><p>Regression models included adjustment for age, gender, years of education and APOE4 status.</p></fn><fn id='T7F1'><p>* Significant at p &lt; 0.05;</p></fn><fn id='T7F2'><p>** significant at p &lt; 0.001.</p></fn></table-wrap-foot></table-wrap></floats-group></article></PAPER>